Photo via flickr by teo_ladodicivideo

The Peripheral and Central Nervous System Drugs advisory committee of the FDA has voted to recommend DaTSCAN, (Ioflupane I 123 Injection). If approved, GE Healthcare’s DaTSCAN™ will be the first radiopharmaceutical agent available to detect DaT (dopamine transporter) distribution within the brain. The proposed indication for DaTSCAN™ is for the visualization by single photon emission computed tomography (SPECT) imaging in patients presenting symptoms or signs of dopaminergic neurodegeneration.

via Reuters

Leave a reply